 <h1>Dacomitinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dacomitinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dacomitinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dacomitinib:</p><p>
<i>More common</i>
</p><ul>
<li>Blistering, crusting, irritation, itching, or reddening of the skin</li>
<li>body aches or pain</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>cracked lips</li>
<li>cracked, dry, or scaly skin</li>
<li>deep cracks, grooves, or lines in the skin</li>
<li>diarrhea</li>
<li>difficulty in swallowing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>itching, skin rash</li>
<li>loosening of the fingernails</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>redness or soreness around the fingernails</li>
<li>redness, swelling, or pain of the skin</li>
<li>runny nose</li>
<li>scaling of the skin on the hands and feet</li>
<li>sneezing</li>
<li>sore throat sores, ulcers, or white spots on the lips, tongue, or inside the mouth</li>
<li>swelling</li>
<li>tightness in the chest</li>
<li>tingling of the hands and feet</li>
<li>trouble breathing</li>
<li>ulceration of the skin</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Confusion</li>
<li>decreased urination</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fever</li>
<li>increase in heart rate</li>
<li>lightheadedness</li>
<li>loss of heat from the body</li>
<li>rapid breathing</li>
<li>sunken eyes</li>
<li>thirst</li>
<li>wrinkled skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dacomitinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, dry, or itching eyes</li>
<li>change in taste</li>
<li>constipation</li>
<li>decreased appetite</li>
<li>decreased weight</li>
<li>discharge, excessive tearing</li>
<li>hair loss or thinning of hair</li>
<li>increased hair growth on the forehead, back, arms, and legs</li>
<li>lack or loss of strength</li>
<li>loss of taste</li>
<li>nausea</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>trouble sleeping</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Eye redness, irritation, or pain</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dacomitinib: oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (44%), hypoalbuminemia (44%), lymphopenia (42%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Pain in extremity (14%), musculoskeletal pain (12%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (19%)</p>
<p><b>Common</b> (1% to 10%): Keratitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperglycemia (36%), hypocalcemia (33%), decreased appetite (31%), decreased weight (26%), hyponatremia (26%), alkaline phosphatase increased (22%), hypomagnesemia (22%)</p>
<p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (40%), AST increased (35%), hyperbilirubinemia (16%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (21%), nasal mucosal disorder (i.e., epistaxis, nasal inflammation, nasal mucosal ulcer, rhinitis) (19%), dyspnea (13%), upper respiratory tract infection (12%), chest pain (10%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (13%)</p>
<p><b>Common</b> (1% to 10%): Fatigue<sup>[Ref]</sup></p><h3>General</h3><p>The most common (greater than 20%) adverse reactions were diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), decreased weight (26%), alopecia (23%), cough (21%), and pruritus (21%).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (24%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (i.e., dermatitis acneiform, rash, rash maculopapular)/exfoliative skin reactions (78%), paronychia (i.e., nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis) (64%), dry skin (i.e., xerosis) (30%), alopecia (30%), pruritus (21%), palmar-plantar erythrodysesthesia syndrome (15%), dermatitis (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (87%), stomatitis (i.e., mucosal inflammation) (45%), nausea (19%) constipation (13%), mouth ulceration (12%)</p>
<p><b>Common</b> (1% to 10%): Vomiting<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of lung cancer is Vizimpro used to treat?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about dacomitinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: EGFR inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dacomitinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Vizimpro</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dacomitinib: oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (44%), hypoalbuminemia (44%), lymphopenia (42%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Pain in extremity (14%), musculoskeletal pain (12%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (19%)</p><p><b>Common</b> (1% to 10%): Keratitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperglycemia (36%), hypocalcemia (33%), decreased appetite (31%), decreased weight (26%), hyponatremia (26%), alkaline phosphatase increased (22%), hypomagnesemia (22%)</p><p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (40%), AST increased (35%), hyperbilirubinemia (16%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (21%), nasal mucosal disorder (i.e., epistaxis, nasal inflammation, nasal mucosal ulcer, rhinitis) (19%), dyspnea (13%), upper respiratory tract infection (12%), chest pain (10%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (13%)</p><p><b>Common</b> (1% to 10%): Fatigue<sup>[Ref]</sup></p><h3>General</h3><p>The most common (greater than 20%) adverse reactions were diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), decreased weight (26%), alopecia (23%), cough (21%), and pruritus (21%).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Creatinine increased (24%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (i.e., dermatitis acneiform, rash, rash maculopapular)/exfoliative skin reactions (78%), paronychia (i.e., nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis) (64%), dry skin (i.e., xerosis) (30%), alopecia (30%), pruritus (21%), palmar-plantar erythrodysesthesia syndrome (15%), dermatitis (11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (87%), stomatitis (i.e., mucosal inflammation) (45%), nausea (19%) constipation (13%), mouth ulceration (12%)</p><p><b>Common</b> (1% to 10%): Vomiting<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of lung cancer is Vizimpro used to treat?</li>
</ul><h2>More about dacomitinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: EGFR inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dacomitinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>